Samsara BioCapital GP, LLC - 14 Nov 2023 Form 4 Insider Report for CARGO Therapeutics, Inc. (CRGX)

Role: 10%+ Owner
Signature: Samsara BioCapital GP, LLC, By /s/ Srinivas Akkaraju, Managing Member
Issuer symbol: CRGX
Transactions as of: 14 Nov 2023
Net transactions value: +$9,999,990
Form type: 4
Filing time: 16 Nov 2023, 19:39:55 UTC
Previous filing: 09 Nov 2023
Next filing: 14 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRGX	Common Stock	Conversion of derivative security		+3,381,323	+4588%		3,455,023	14 Nov 2023	By Samsara BioCapital, L.P.	F1, F2
transaction	CRGX	Common Stock	Purchase	$9,999,990	+666,666	+19%	$15.00	4,121,689	14 Nov 2023	By Samsara BioCapital, L.P.	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Date	Underlying Class	Amount	Ownership	Footnotes
transaction	CRGX	Series Seed convertible preferred stock	Conversion of derivative security	$0	-663,300	-100%	$0.000000^*	14 Nov 2023	Common Stock	663,300	By Samsara BioCapital, L.P.	F1, F2
transaction	CRGX	Series A-1 convertible preferred stock	Conversion of derivative security	$0	-884,400	-100%	$0.000000^*	14 Nov 2023	Common Stock	884,400	By Samsara BioCapital, L.P.	F1, F2
transaction	CRGX	Series A-2 convertible preferred stock	Conversion of derivative security	$0	-1,833,623	-100%	$0.000000^*	14 Nov 2023	Common Stock	1,833,623	By Samsara BioCapital, L.P.	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date.
F2	Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.

Content

Each share of Series Seed convertible preferred stock, Series A-1 convertible preferred stock and Series A-2 convertible preferred stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date.

Shares are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.